CN115427043A - FXIa抑制剂化合物或其盐的医药用途 - Google Patents

FXIa抑制剂化合物或其盐的医药用途 Download PDF

Info

Publication number
CN115427043A
CN115427043A CN202180030744.6A CN202180030744A CN115427043A CN 115427043 A CN115427043 A CN 115427043A CN 202180030744 A CN202180030744 A CN 202180030744A CN 115427043 A CN115427043 A CN 115427043A
Authority
CN
China
Prior art keywords
salt
compound
thrombosis
use according
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180030744.6A
Other languages
English (en)
Other versions
CN115427043B (zh
Inventor
肖瑛
吴俊军
邢伟
王汝欢
黄伟鑫
陆银锁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Publication of CN115427043A publication Critical patent/CN115427043A/zh
Application granted granted Critical
Publication of CN115427043B publication Critical patent/CN115427043B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

提供了一种FXIa抑制剂化合物或其盐的医药用途，具体涉及其在制备预防和/或治疗动脉和静脉血栓药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180030744.6A 2020-10-23 2021-10-22 FXIa抑制剂化合物或其盐的医药用途 Active CN115427043B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020111531599 2020-10-23
CN202011153159 2020-10-23
CN202110257407 2021-03-09
CN2021102574072 2021-03-09
PCT/CN2021/125450 WO2022083707A1 (zh) 2020-10-23 2021-10-22 FXIa抑制剂化合物或其盐的医药用途

Publications (2)

Publication Number Publication Date
CN115427043A true CN115427043A (zh) 2022-12-02
CN115427043B CN115427043B (zh) 2023-04-07

Family

ID=81289681

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180030744.6A Active CN115427043B (zh) 2020-10-23 2021-10-22 FXIa抑制剂化合物或其盐的医药用途

Country Status (3)

Country Link
CN (1) CN115427043B (zh)
TW (1) TW202227079A (zh)
WO (1) WO2022083707A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515938A (zh) * 2020-10-23 2022-12-23 深圳信立泰药业股份有限公司 FXIa抑制剂化合物的盐及其制备方法和医药用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026996A (zh) * 2008-03-13 2011-04-20 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
WO2017023992A1 (en) * 2015-08-05 2017-02-09 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors
US20170291892A1 (en) * 2014-09-24 2017-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2018041122A1 (zh) * 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
CN114206854B (zh) * 2019-09-27 2023-02-24 深圳信立泰药业股份有限公司 FXIa抑制剂及其制备方法和医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112675173B (zh) * 2020-12-25 2022-04-05 华南理工大学 FXIa抑制剂化合物或其盐的医药用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026996A (zh) * 2008-03-13 2011-04-20 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
US20170291892A1 (en) * 2014-09-24 2017-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2017023992A1 (en) * 2015-08-05 2017-02-09 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors
WO2018041122A1 (zh) * 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN107793396A (zh) * 2016-08-31 2018-03-13 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
CN114206854B (zh) * 2019-09-27 2023-02-24 深圳信立泰药业股份有限公司 FXIa抑制剂及其制备方法和医药用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515938A (zh) * 2020-10-23 2022-12-23 深圳信立泰药业股份有限公司 FXIa抑制剂化合物的盐及其制备方法和医药用途

Also Published As

Publication number Publication date
TW202227079A (zh) 2022-07-16
WO2022083707A1 (zh) 2022-04-28
CN115427043B (zh) 2023-04-07

Similar Documents

Publication Publication Date Title
CN112675173B (zh) FXIa抑制剂化合物或其盐的医药用途
EP2906551B1 (en) Crystalline forms of a factor xia inhibitor
JP4256160B2 (ja) プロテアーゼ阻害剤としての、アミノピリジニル、アミノグアニジニル、およびアルコキシグアニジニルで置換されたフェニルアセトアミド
JP2021523887A (ja) ＸＩＩａ因子インヒビター
BRPI0610506A2 (pt) moduladores de trombina de n-óxidos de piridina fluorados e processo para n-oxidação de heteroarilas contendo nitrogênio
CN115427043B (zh) FXIa抑制剂化合物或其盐的医药用途
JPH04503524A (ja) 再潅流損傷の防止又は制限のための薬剤
US20210253550A1 (en) Therapeutic compounds and compositions
CN105732595A (zh) 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途
WO2017162157A1 (zh) 内磺酰胺化合物及其使用方法
WO2022083706A1 (zh) FXIa抑制剂化合物的盐及其制备方法和医药用途
WO2022171151A1 (zh) 一种smtp-7衍生物及其用途
TW200526642A (en) Heterocyclic derivatives
WO2021110076A1 (zh) 草酰胺类衍生物、其制备方法及其在医药上的应用
JP2018520128A (ja) 重水素化チエノピペリジン誘導体、調製方法、及びその使用
CN116947818B (zh) 一种氧代吡啶类化合物、中间体及其制备方法和用途
US11225462B2 (en) Crystal forms of oxypyridine amide derivative and preparation method therefor
CN102770416B (zh) 美他沙酮共晶体
CN108912142B (zh) 吡咯并苯并恶嗪酮类化合物及其注射剂和在抗血栓中的用途
CN117164565A (zh) 一种新型氧代嘧啶类化合物及其制备方法和用途
CN117164561A (zh) 一种氧代嘧啶类化合物及其制备方法和用途
CN117164566A (zh) 一种新型氧代哒嗪类化合物及其制备方法和用途
CN117164564A (zh) 新型氧代哒嗪类化合物及其制备方法和用途
CN114728914A (zh) 二氧代哌嗪类衍生物、其制备方法及其在医药上的应用
CN117186073A (zh) 新的氧代嘧啶类化合物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant